These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36607429)

  • 21. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.
    Zeng Y; Lockhart AC; Jin RU
    Expert Opin Drug Discov; 2024 Aug; 19(8):873-886. PubMed ID: 38919123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE; Ajani J
    Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
    Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
    Huang Y; You M; Wu Q; Chen R
    Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
    [No Abstract]   [Full Text] [Related]  

  • 26. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
    Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
    Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
    Shah MA; Starodub A; Sharma S; Berlin J; Patel M; Wainberg ZA; Chaves J; Gordon M; Windsor K; Brachmann CB; Huang X; Vosganian G; Maltzman JD; Smith V; Silverman JA; Lenz HJ; Bendell JC
    Clin Cancer Res; 2018 Aug; 24(16):3829-3837. PubMed ID: 29691300
    [No Abstract]   [Full Text] [Related]  

  • 30. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
    Front Immunol; 2022; 13():885424. PubMed ID: 35837391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
    Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
    JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
    Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
    Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
    Kawakami H
    Int J Clin Oncol; 2024 Sep; 29(9):1228-1236. PubMed ID: 38630383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets.
    Kinugasa F; Kajikawa S; Weng J; Ugawa T; Fushiki H; Yamanaka Y; Nagata M; Haggerty G; Akuzawa S; Nakazawa T; Suzuki H; Sawamoto T
    J Pharmacol Sci; 2024 Nov; 156(3):161-170. PubMed ID: 39313274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Kelly RJ; Lee J; Bang YJ; Almhanna K; Blum-Murphy M; Catenacci DVT; Chung HC; Wainberg ZA; Gibson MK; Lee KW; Bendell JC; Denlinger CS; Chee CE; Omori T; Leidner R; Lenz HJ; Chao Y; Rebelatto MC; Brohawn PZ; He P; McDevitt J; Sheth S; Englert JM; Ku GY
    Clin Cancer Res; 2020 Feb; 26(4):846-854. PubMed ID: 31676670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
    BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.